Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Amneal Pharmaceuticals LLC and Zydus Pharmaceuticals (USA) Inc.'s proposed generic versions of the pulmonary arterial hypertension drug Opsumit infringe Actelion Pharmaceuticals Ltd.'s patent on the orphan drug, Actelion said.
In a suit filed Jan. 31 in the U.S. District Court for the District of New Jersey, Actelion asked the court to block the Food and Drug Administration from approving the generics until October 2022, when U.S. Patent No. 7,094,781 expires. Opsumit has orphan drug status, which means it gets special incentives including tax credits and an extra seven years of marketing exclusivity upon FDA approval.
Opsumit has produced strong results for Actelion despite the small patient population with PAH. In fact, specialty drugs for rare disorders often carry a significant price tag. For example, the out-of-pocket cost for Opsumit oral tablet 10 mg even with a drug discount card is more than $4,700 for just 15 tablets, according to the site Drugs.com.
Opsumit is indicated to treat PAH to delay disease progression.
Actelion’s strong track record in PAH drugs was a big selling point for Johnson & Johnson, which is expected to close a deal to purchase Actelion in the second quarter. Access to Opsumit, along with Actelion’s drugs Tracleer and Uptravi, which also treat life-threatening PAH, will make J&J a leader in treating PAH and help it expand its disease portfolio beyond autoimmune, heart, and cancer drugs.
Orphan drugs treat rare diseases affecting fewer than 200,000 people in the U.S. Actelion holds the approved New Drug Application (NDA) for Opsumit (macitentan) 10 mg oral once-a-day tablets. The FDA granted Opsumit an additional seven years of exclusivity that expires Oct. 18, 2020.
The ‘781 patent is titled sulfamides and their use as endothelin receptor antagonists and is listed in the FDA’s Orange Book, a listing of patents branded drug companies claim cover their drug products.
Actelion is a Swiss corporation. Zydus, a subsidiary of Indian company Cadila Healthcare Ltd., is based in Pennington, N.J. Amneal is based in Bridgewater, N.J.
Paul Hastings LLP and Saul Ewing Arnstein & Lehr LLP represent Actelion.
The case is Actelion Pharmaceuticals Ltd. v. Zydus Pharmaceuticals (USA), Inc. , D.N.J., No. 3:18-cv-01397, complaint filed 1/31/18
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The lawsuit is at http://src.bna.com/v7t.
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)